Tsai-Der Chuang1, Derek Quintanilla1, Drake Boos1, Omid Khorram2. 1. Department of Obstetrics and Gynecology, Harbor-University of California-Los Angeles Medical Center and The Lundquist Institute, Torrance, California. 2. Department of Obstetrics and Gynecology, Harbor-University of California-Los Angeles Medical Center and The Lundquist Institute, Torrance, California. Electronic address: okhorram@lundquist.org.
Abstract
OBJECTIVE: To determine the expression and functional roles of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) in leiomyoma. DESIGN: Experimental study. SETTING: Academic research laboratory. PATIENT(S): Women undergoing hysterectomy for leiomyoma. INTERVENTION(S): Blockade of IDO1 and TDO2. MAIN OUTCOME MEASURE(S): Expression of IDO1 and TDO2 in leiomyoma and the effects of their inhibitors on the extracellular matrix. RESULT(S): Leiomyoma expressed significantly higher levels of IDO1 and TDO2 messenger ribonucleic acid (mRNA; 60.3%, 35/58 pairs and 98.3%, 57/58 pairs, respectively) and protein (54%, 27/50 pairs and 92%, 46/50 pairs, respectively) as well as the enzyme activity marker kynurenine (78.3%, 36/46 pairs for IDO1/TDO2) compared with levels in matched myometrium. The expression of TDO2 but not IDO1 mRNA was significantly higher in fibroids from African American compared with that in Caucasian and Hispanic patients. The TDO2 but not the IDO1 protein and mRNA levels were more abundant in fibroids bearing the MED12 mutation compared with results in wild-type leiomyomas. Treatment of leiomyoma smooth muscle cell and myometrial smooth muscle cell spheroids with the TDO2 inhibitor 680C91 but not the IDO1 inhibitor epacadostat significantly repressed cell proliferation and the expression of collagen type I (COL1A1) and type III (COL3A1) in a dose-dependent manner; these effects were more pronounced in leiomyoma smooth muscle cells compared with myometrial smooth muscle cell spheroids. CONCLUSION(S): These results underscore the physiological significance of the tryptophan degradation pathway in the pathogenesis of leiomyomas and the potential utility of anti-TDO2 drugs for treatment of leiomyomas.
OBJECTIVE: To determine the expression and functional roles of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) in leiomyoma. DESIGN: Experimental study. SETTING: Academic research laboratory. PATIENT(S): Women undergoing hysterectomy for leiomyoma. INTERVENTION(S): Blockade of IDO1 and TDO2. MAIN OUTCOME MEASURE(S): Expression of IDO1 and TDO2 in leiomyoma and the effects of their inhibitors on the extracellular matrix. RESULT(S): Leiomyoma expressed significantly higher levels of IDO1 and TDO2 messenger ribonucleic acid (mRNA; 60.3%, 35/58 pairs and 98.3%, 57/58 pairs, respectively) and protein (54%, 27/50 pairs and 92%, 46/50 pairs, respectively) as well as the enzyme activity marker kynurenine (78.3%, 36/46 pairs for IDO1/TDO2) compared with levels in matched myometrium. The expression of TDO2 but not IDO1 mRNA was significantly higher in fibroids from African American compared with that in Caucasian and Hispanic patients. The TDO2 but not the IDO1 protein and mRNA levels were more abundant in fibroids bearing the MED12 mutation compared with results in wild-type leiomyomas. Treatment of leiomyoma smooth muscle cell and myometrial smooth muscle cell spheroids with the TDO2 inhibitor 680C91 but not the IDO1 inhibitor epacadostat significantly repressed cell proliferation and the expression of collagen type I (COL1A1) and type III (COL3A1) in a dose-dependent manner; these effects were more pronounced in leiomyoma smooth muscle cells compared with myometrial smooth muscle cell spheroids. CONCLUSION(S): These results underscore the physiological significance of the tryptophan degradation pathway in the pathogenesis of leiomyomas and the potential utility of anti-TDO2 drugs for treatment of leiomyomas.
Authors: Teresa A Almeida; Antonieta Quispe-Ricalde; Francisco Montes de Oca; Pilar Foronda; Mariano M Hernández Journal: Gynecol Oncol Date: 2014-04-24 Impact factor: 5.482
Authors: Netta Mäkinen; Miika Mehine; Jaana Tolvanen; Eevi Kaasinen; Yilong Li; Heli J Lehtonen; Massimiliano Gentile; Jian Yan; Martin Enge; Minna Taipale; Mervi Aavikko; Riku Katainen; Elina Virolainen; Tom Böhling; Taru A Koski; Virpi Launonen; Jari Sjöberg; Jussi Taipale; Pia Vahteristo; Lauri A Aaltonen Journal: Science Date: 2011-08-25 Impact factor: 47.728
Authors: Olga Protic; Paolo Toti; Md Soriful Islam; Rossella Occhini; Stefano Raffaele Giannubilo; William H Catherino; Saverio Cinti; Felice Petraglia; Andrea Ciavattini; Mario Castellucci; Boris Hinz; Pasquapina Ciarmela Journal: Cell Tissue Res Date: 2015-11-27 Impact factor: 5.249
Authors: Anne P Hutchinson; Ping Yin; Ilona Neale; John S Coon; Stacy A Kujawa; Shimeng Liu; Serdar E Bulun Journal: Reprod Sci Date: 2022-01-21 Impact factor: 3.060